Literature DB >> 9714242

The replicative impairment of Vif- mutants of human immunodeficiency virus type 1 correlates with an overall defect in viral DNA synthesis.

M Nascimbeni1, M Bouyac, F Rey, B Spire, F Clavel.   

Abstract

The Vif protein of human immunodeficiency virus type 1 (HIV-1) is essential for the infectivity of virions produced by non-permissive cells. The primary replicative defect of Vif particles involves either synthesis or stability of viral DNA, but the mechanism of this defect is unknown. Here, we report the results of a detailed analysis of HIV-1 DNA synthesis by isogenic Vif- mutants produced by different chronically infected H9 clones, which exhibit different degrees of impairment in their replicative capacity. We found that the degree of impairment of DNA synthesis by the mutant particles always correlated with the degree of their loss of infectivity. This impairment appears to be global, with a defect increasing along with synthesis of longer viral DNA species. We conclude that the primary replicative defect of Vif- virus involves the capacity of the reverse transcription complex of HIV-1 to efficiently elongate viral DNA, resulting in an inability to produce full-length viral DNA genomes.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9714242     DOI: 10.1099/0022-1317-79-8-1945

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  18 in total

1.  Vif is an auxiliary factor of the HIV-1 reverse transcriptase and facilitates abasic site bypass.

Authors:  Reynel Cancio; Silvio Spadari; Giovanni Maga
Journal:  Biochem J       Date:  2004-11-01       Impact factor: 3.857

2.  Inhibitors of human immunodeficiency virus type 1 reverse transcriptase target distinct phases of early reverse transcription.

Authors:  C W Hooker; W B Lott; D Harrich
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

Review 3.  HIV Genome-Wide Protein Associations: a Review of 30 Years of Research.

Authors:  Guangdi Li; Erik De Clercq
Journal:  Microbiol Mol Biol Rev       Date:  2016-06-29       Impact factor: 11.056

4.  Human immunodeficiency virus type 1 Vif protein is packaged into the nucleoprotein complex through an interaction with viral genomic RNA.

Authors:  M A Khan; C Aberham; S Kao; H Akari; R Gorelick; S Bour; K Strebel
Journal:  J Virol       Date:  2001-08       Impact factor: 5.103

5.  Identification of a functionally important amino acid residue near to the amino-terminus of the human immunodeficiency virus type 1 Vif protein.

Authors:  M Boyce; P Willingmann; M McCrae
Journal:  Virus Genes       Date:  1999       Impact factor: 2.332

6.  Association of human immunodeficiency virus type 1 Vif with RNA and its role in reverse transcription.

Authors:  M Dettenhofer; S Cen; B A Carlson; L Kleiman; X F Yu
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

7.  Role of Vif in stability of the human immunodeficiency virus type 1 core.

Authors:  A Ohagen; D Gabuzda
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

Review 8.  Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors.

Authors:  Simon Henriet; Gaëlle Mercenne; Serena Bernacchi; Jean-Christophe Paillart; Roland Marquet
Journal:  Microbiol Mol Biol Rev       Date:  2009-06       Impact factor: 11.056

9.  Influence of primate lentiviral Vif and proteasome inhibitors on human immunodeficiency virus type 1 virion packaging of APOBEC3G.

Authors:  Bindong Liu; Xianghui Yu; Kun Luo; Yunkai Yu; Xiao-Fang Yu
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

10.  Mutational analysis of the HIV-1 auxiliary protein Vif identifies independent domains important for the physical and functional interaction with HIV-1 reverse transcriptase.

Authors:  Alexandra Kataropoulou; Chiara Bovolenta; Amalia Belfiore; Sonia Trabatti; Anna Garbelli; Simona Porcellini; Rossella Lupo; Giovanni Maga
Journal:  Nucleic Acids Res       Date:  2009-04-15       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.